{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:17:47Z","timestamp":1784330267962,"version":"3.55.0"},"reference-count":327,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The rising global incidence and dismal prognosis of cholangiocarcinoma (CCA) underscore the profound limitations of standard therapies. While chimeric antigen receptor (CAR)-based cellular immunotherapies represent a paradigm shift in oncology, their success in CCA is fundamentally constrained by a desmoplastic, immunosuppressive tumour microenvironment (TME) and significant tumour antigen heterogeneity. This review advances the thesis that overcoming these barriers requires an integrated approach combining multi-antigen, armoured CAR designs with rational adjuvant strategies (i.e combination therapy). We provide a comparative analysis of key tumour-associated antigens (TAAs)-including MUC1, c-MET, and the cancer stem cell marker CD133-evaluating their expression profiles, preclinical efficacy, and clinical status. The review further deconstructs the core mechanisms of therapeutic resistance in CCA-spanning physical, immunological, and metabolic barriers-and map them to next-generation engineering strategies designed to counteract them. In a novel synthesis, we explore the synergistic potential of combining CAR therapies with checkpoint inhibitors and immunomodulatory natural compounds. Critically appraising the current clinical trial landscape, we identify key weaknesses and propose strategic recommendations for biomarker-driven, adaptive trial designs. Finally, we present a forward-looking, four-pillar roadmap for future research, positioning the integration of advanced CAR engineering, multi-antigen platforms, synergistic adjuvants, and alternative effectors as the definitive research agenda for translating the promise of cellular immunotherapy into a clinical reality for CCA.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1757504","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:40Z","timestamp":1778219680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Saied","family":"Froghi","sequence":"first","affiliation":[{"name":"Division of Surgery & Interventional Sciences, Royal Free Hospital, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astero","family":"Klampatsa","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Immunotherapy Group, Division of Cancer Biology, Institute of Cancer Research","place":["Sutton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Davidson","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Sciences, Royal Free Hospital, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384314","article-title":"Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019","volume":"11","author":"Su","year":"2024","journal-title":"Front Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v5.i7.171","article-title":"Chemotherapy for cholangiocarcinoma: an update","volume":"5","author":"Ram\u00edrez-Merino","year":"2013","journal-title":"World J Gastrointest Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14100","article-title":"Medical treatment for cholangiocarcinoma","volume":"39","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ol.2020.12244","article-title":"Latest evidence on immunotherapy for cholangiocarcinoma","volume":"20","author":"Guo","year":"2020","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/jco.2020.38.15_suppl.4520","article-title":"Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \u00b1 tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advanced biliary tract cancer (aBTC)","volume":"38","author":"Oh","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1037945","article-title":"Immune microenvironment of cholangiocarcinoma: biological concepts and treatment strategies","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ijo.2023.5585","article-title":"Tumour immune microenvironment and the current immunotherapy of cholangiocarcinoma (review)","volume":"63","author":"Yang","year":"2023","journal-title":"Int J Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1865308","article-title":"Targeting the tumour microenvironment in cholangiocarcinoma: implications for therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Expert Opin Invest Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2024.72","article-title":"Advancing immunotherapy for intrahepatic cholangiocarcinoma: exploring the tumour immune microenvironment and innovative treatments","volume":"10","author":"Pengcheng","year":"2024","journal-title":"Hepatoma Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183232","article-title":"Advancing cholangiocarcinoma care: insights and innovations in T cell therapy","volume":"16","author":"Dadgar","year":"2024","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112273","article-title":"Precision immunotherapy for cholangiocarcinoma: pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells","volume":"136","author":"Chiawpanit","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1559465","article-title":"Advancing biliary tract Malignancy treatment: emerging frontiers in cell-based therapies","volume":"16","author":"Ao","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/immuno5030040","article-title":"Immune landscape of intrahepatic cholangiocarcinoma: evasion and therapeutic insights","volume":"5","author":"Porro","year":"2025","journal-title":"Immuno"},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumour treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","article-title":"CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s474348","article-title":"Focusing on the immune cells: recent advances in immunotherapy for biliary tract cancer","volume":"16","author":"Ni","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337557","article-title":"Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142397","article-title":"Engineering innate immunity: recent advances and future directions for CAR-NK and CAR\u2013macrophage therapies in solid tumours","volume":"17","author":"Amoozgar","year":"2025","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03443-7","article-title":"Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma","volume":"398","author":"Ren","year":"2025","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002818","article-title":"Chimeric antigen receptor-immune cells against solid tumours: structures, mechanisms, recent advances, and future developments","volume":"137","author":"Li","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumour immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B26","volume-title":"A phase 1 open-label, multi-centre first in human study of TnMUC1-targeted genetically-modified chimeric antigen receptor T cells in patients with advanced TnMUC1-positive solid tumours and multiple myeloma","year":"2019"},{"key":"B27","volume-title":"A phase 1 dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic solid tumours","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025608","article-title":"Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B30","volume-title":"Tumour microenvironment and immunology of cholangiocarcinoma","year":"2022"},{"key":"B31","volume-title":"Clinical study of chimeric CD(cluster of differentiation)133 antigen receptor-modified T cells in relapsed and\/or chemotherapy refractory Malignancies","year":"2015"},{"key":"B32","volume-title":"Clinical study of chimeric EGFR antigen receptor-modified T cells in chemotherapy refractory advanced solid tumours","year":"2013"},{"key":"B33","volume-title":"Clinical study of redirected autologous T cells with a Claudin18.2-targeted chimeric antigen receptor in patients with advanced gastric adenocarcinoma and pancreatic adenocarcinoma","author":"Carsgen Therapeutics Co","year":"2017"},{"key":"B34","volume-title":"An open label, single\/multiple dose exploratory clinical study to evaluate the safety, efficacy, and cytokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumour subjects","author":"Carsgen Therapeutics Co","year":"2019"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000485","article-title":"Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact","volume":"22","author":"Park","year":"2009","journal-title":"Oncol Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.22541\/au.159863482.20648477","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10398","article-title":"Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma","volume":"94","author":"Matsumura","year":"2002","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/cji.0000000000000460","article-title":"Development of engineered CAR T cells targeting tumour-associated glycoforms of MUC1 for the treatment of intrahepatic cholangiocarcinoma","volume":"46","author":"Mao","year":"2023","journal-title":"J Immunother"},{"key":"B39","volume-title":"Phase I\/II study of anti-MUC1 CAR T cells for patients with MUC1+ advanced refractory solid tumour","author":"The First People's Hospital of","year":"2015"},{"key":"B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jss.2006.05.031","article-title":"Involvement of c-Met\/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met","volume":"136","author":"Leelawat","year":"2006","journal-title":"J Surg Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.199","article-title":"Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma","volume":"105","author":"Miyamoto","year":"2011","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.152857","article-title":"C-MET in intrahepatic cholangiocarcinoma: high-frequency amplification predicts protein expression and a unique molecular subtype","volume":"216","author":"Pu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.2990","article-title":"c-Met targeted therapy of cholangiocarcinoma","volume":"14","author":"Socoteanu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i9.1192","article-title":"Strong expression of CD133 is associated with increased cholangiocarcinoma progression","volume":"17","author":"Leelawat","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s00535-010-0235-3","article-title":"CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma","volume":"45","author":"Shimada","year":"2010","journal-title":"J Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-320","article-title":"CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma","volume":"11","author":"Fan","year":"2011","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Haematol Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/jco.2017.35.15_suppl.3042","article-title":"CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic Malignancies","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3261","article-title":"Characterization of EGFR family gene aberrations in cholangiocarcinoma","volume":"32","author":"Yang","year":"2014","journal-title":"Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1590\/0100-6991e-20181826","article-title":"Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival","volume":"45","author":"Gomes","year":"2018","journal-title":"Rev Col Bras Cir"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.033","article-title":"EGF\/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition","volume":"61","author":"Clap\u00e9ron","year":"2014","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101172","article-title":"Mitogen-Activated Protein Kinases (MAPKs) and cholangiocarcinoma: The missing link","volume":"8","author":"Chen","year":"2019","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064186","article-title":"EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma","volume":"8","author":"Hoffmann","year":"2013","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1089488","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0432","article-title":"Phase I study of chimeric antigen receptor\u2013modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract Malignancies; systematic review and meta-analysis: A potential therapeutic target","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/jco.2025.43.4_suppl.629","article-title":"Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1321-0","article-title":"HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma","volume":"461","author":"Lee","year":"2012","journal-title":"Virchows Arch"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e15203","article-title":"Prognosis of HER2 expression in cholangiocarcinoma when evaluated using gastric cancer methodology of immunohistochemistry","volume":"33","author":"Fernandes","year":"2015","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): A multicentre, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01193-x","article-title":"Claudin-18.2 and Trop-2 as emerging biomarkers in biliary tract cancers: Expression analysis and therapeutic potential","author":"Shin","year":"2025","journal-title":"Target Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2024-925","article-title":"Claudin 18 immunohistochemistry in cholangiocarcinoma","volume":"16","author":"Desai","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-011-1092-z","article-title":"Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma","volume":"459","author":"Shinozaki","year":"2011","journal-title":"Virchows Arch"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: A promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/his.15407","article-title":"Expression of claudin-18.2 in cholangiocarcinoma: A comprehensive immunohistochemical analysis from a German tertiary centre","volume":"86","author":"Kinzler","year":"2025","journal-title":"Histopathology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2400209","article-title":"Open-label, multicenter, phase 1b\/2 clinical trial to evaluate the safety and efficacy of autologous anti-claudin 18.2 chimeric antigen receptor T-cell therapy in subjects with advanced gastric, pancreatic, or other specified digestive system cancers","volume":"15","year":"2020"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1636367","article-title":"Claudin18.2 defines a prognostically distinct subgroup of intrahepatic cholangiocarcinoma via CD8+ T-cell exclusion","volume":"15","author":"Yu","year":"2025","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040857","article-title":"The role of NK cells in cancer immunotherapy: Mechanisms, evasion strategies, and therapeutic advances","volume":"13","author":"Morcillo-Mart\u00edn-Romo","year":"2025","journal-title":"Biomedicines"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72534","article-title":"Tumour heterogeneity reshapes the tumour microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumour-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00537-5","article-title":"Multi-specific CAR targeting to prevent antigen escape","volume":"14","author":"Walsh","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B78","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0442","article-title":"Tumour antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic tumour microenvironment and immunotherapy in cholangiocarcinoma","volume":"4","author":"H\u00f8gdall","year":"2018","journal-title":"Trends Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040319","article-title":"Cancer-associated fibroblasts and extracellular matrix: Therapeutical strategies for modulating the cholangiocarcinoma microenvironment","volume":"30","author":"Minini","year":"2023","journal-title":"Curr Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.2010046","article-title":"Cholangiocarcinoma: What are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells","volume":"25","author":"Wang","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The role of cancer-associated fibroblasts and fibrosis in liver cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12982","article-title":"Cancer-associated fibroblasts: Key players in shaping the tumour immune microenvironment","volume":"302","author":"Desbois","year":"2021","journal-title":"Immunol Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102885","article-title":"The role of stroma in cholangiocarcinoma: The intriguing interplay between fibroblastic component, immune cell subsets and tumour epithelium","volume":"19","author":"Gentilini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B88","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s42255-022-00582-0","article-title":"Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix","volume":"4","author":"Kay","year":"2022","journal-title":"Nat Metab"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-025-07388-4","article-title":"TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8\u2009+\u2009T cell exhaustion: Implications for immunotherapy","volume":"16","author":"Tang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482291","article-title":"Infiltrating T lymphocytes and tumour microenvironment within cholangiocarcinoma: Immune heterogeneity, intercellular communication, immune checkpoints","volume":"15","author":"Dai","year":"2025","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2022.98","article-title":"The role of tumour microenvironment in cholangiocarcinoma","volume":"9","author":"Maria Eva","year":"2023","journal-title":"Hepatoma Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/0115680096267791231115101107","article-title":"The tumour immune microenvironment plays a key role in driving the progression of cholangiocarcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"B94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-030-65908-0_14","article-title":"The tumour microenvironment in cholangiocarcinoma progression","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2023.23","article-title":"Cholangiocarcinoma tumour microenvironment highlighting fibrosis and matrix components","author":"Caligiuri","year":"2023","journal-title":"Hepatoma Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16443","article-title":"Targeting cancer-associated fibroblasts: Eliminate or reprogram","volume":"116","author":"Yamazaki","year":"2025","journal-title":"Cancer Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-023-02934-4","article-title":"Transcription factors in fibroblast plasticity and CAF heterogeneity","volume":"42","author":"Melchionna","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12967-025-06306-8","article-title":"Mechanical forces in the tumour microenvironment: Roles, pathways, and therapeutic approaches","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/liv.14098","article-title":"The tumour microenvironment and immune milieu of cholangiocarcinoma","volume":"39","author":"Fabris","year":"2019","journal-title":"Liver Int"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090960","article-title":"Transforming growth factor-beta (TGF\u03b2) signalling pathway in cholangiocarcinoma","volume":"8","author":"Papoutsoglou","year":"2019","journal-title":"Cells"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26114973","article-title":"Inhibiting the TGF-\u03b21 pathway reduces the aggressiveness of intrahepatic CCA HuCCT1 CD90-positive cells","volume":"26","author":"Pizzuto","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102035","article-title":"ETV4 promotes the progression of cholangiocarcinoma by regulating glycolysis via the TGF-\u03b2 signalling","volume":"47","author":"Liu","year":"2024","journal-title":"Transl Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1186\/s12967-024-05857-6","article-title":"Targeting PDGF-CC as a promising therapeutic strategy to inhibit cholangiocarcinoma progression","volume":"22","author":"Luo","year":"2024","journal-title":"J Transl Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26384","article-title":"Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma","volume":"58","author":"Cadamuro","year":"2013","journal-title":"Hepatology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02687.x","article-title":"Targeting PDGFR-\u03b2 in cholangiocarcinoma","volume":"32","author":"Fingas","year":"2012","journal-title":"Liver Int"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010009","article-title":"CP-673451, a selective platelet-derived growth factor receptor tyrosine kinase inhibitor, induces apoptosis in Opisthorchis viverrini-associated cholangiocarcinoma via Nrf2 suppression and enhanced ROS","volume":"17","author":"Duangdara","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B107","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2023.11.302","article-title":"Fibroblast-derived lysyl oxidase increases oxidative phosphorylation and stemness in cholangiocarcinoma","volume":"166","author":"Lewinska","year":"2024","journal-title":"Gastroenterology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2016.03.044","article-title":"Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma","volume":"203","author":"Bergeat","year":"2016","journal-title":"J Surg Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050729","article-title":"Interplay between LOX enzymes and integrins in the tumour microenvironment","volume":"11","author":"Amendola","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.03.017","article-title":"67 laminin receptor promotes the Malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma","volume":"46","author":"Xu","year":"2014","journal-title":"Dig Liver Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4837","article-title":"The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma","volume":"55","author":"Peng","year":"2019","journal-title":"Int J Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14151","article-title":"CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis","volume":"110","author":"Miyata","year":"2019","journal-title":"Cancer Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668349","article-title":"CAFs interacting with TAMs in tumour microenvironment to enhance tumorigenesis and immune evasion","volume":"11","author":"Gunaydin","year":"2021","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0103-8","article-title":"Blockade of CXCL12\/CXCR4 signalling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway","volume":"33","author":"Zhao","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082215","article-title":"Role of chemokines in the biology of cholangiocarcinoma","volume":"12","author":"Caligiuri","year":"2020","journal-title":"Cancers"},{"key":"B116","first-page":"95","article-title":"VEGF and cholangiocarcinoma: Feeding the tumour","volume":"1","author":"Cherry-Bohannan","year":"2011","journal-title":"Trans Gastrointestinal Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100251","article-title":"New insights on the role of vascular endothelial growth factor in biliary pathophysiology","volume":"3","author":"Mariotti","year":"2021","journal-title":"JHEP Rep"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumour microenvironment via STAT3-CCL2 signalling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216498","article-title":"Cancer-associated fibroblasts in cholangiocarcinoma: Current knowledge and possible implications for therapy","volume":"11","author":"Montori","year":"2022","journal-title":"J Clin Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10238-024-01460-7","article-title":"Strategies for treating the cold tumours of cholangiocarcinoma: Core concepts and future directions","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Exp Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70700","article-title":"Hypoxia-inducible factor 1-alpha (HIF-1alpha) and cancer: Mechanisms of tumour hypoxia and therapeutic targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3865","article-title":"Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signalling pathway","volume":"12","author":"Vanichapol","year":"2015","journal-title":"Mol Med Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumours","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s12029-024-01054-2","article-title":"CAR-T cell therapy in pancreatic and biliary tract cancers: An updated review of clinical trials","volume":"55","author":"Drougkas","year":"2024","journal-title":"J Gastrointestinal Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-5154","article-title":"Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumour cell adhesion and invasion","volume":"68","author":"Guti\u00e9rrez-Fern\u00e1ndez","year":"2008","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01302.x","article-title":"Matrix metalloproteinases: Protective roles in cancer","volume":"15","author":"Decock","year":"2011","journal-title":"J Cell Mol Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207255","article-title":"MMP-9 inhibition promotes anti-tumour immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumours","volume":"13","author":"Juric","year":"2018","journal-title":"PLoS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603043","article-title":"Towards third generation matrix metalloproteinase inhibitors for cancer therapy","volume":"94","author":"Overall","year":"2006","journal-title":"Br J Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.830208","article-title":"Key players of the immunosuppressive tumour microenvironment and emerging therapeutic strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumour microenvironment: New findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2024.02.03.578669","DOI":"10.1055\/s-0043-1777599","article-title":"Shift in cellular crosstalk reveals the immunosuppressive environment in cholangiocarcinoma patients","author":"Heij","year":"2024","journal-title":"bioRxiv"},{"key":"B137","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Haematol Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1159\/000518104","article-title":"Immune checkpoint inhibitors: The emerging cornerstone in cholangiocarcinoma therapy","volume":"10","author":"Guti\u00e9rrez-Larra\u00f1aga","year":"2021","journal-title":"Liver Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102191","article-title":"Prognostic role of immune checkpoint regulators in cholangiocarcinoma: A pilot study","volume":"10","author":"Cao","year":"2021","journal-title":"J Clin Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109526","article-title":"Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches","volume":"114","author":"Vatankhah","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-025-14459-4","article-title":"Efficacy and safety outcomes of PD-1\/PD-L1 inhibitors in recurrent cholangiocarcinoma: A real-world, multicentre and retrospective study","volume":"25","author":"Lin","year":"2025","journal-title":"BMC Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/his.13238","article-title":"PD-L1 expression in extrahepatic cholangiocarcinoma","volume":"71","author":"Walter","year":"2017","journal-title":"Histopathology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12935-021-02081-w","article-title":"Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients","volume":"21","author":"Deng","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B144","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1245\/s10434-019-08033-z","article-title":"Clinical significance of PD-L1 expression in both cancer and stroma cells of cholangiocarcinoma patients","volume":"27","author":"Kitano","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.06.006","article-title":"Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy","volume":"32","author":"Gondaliya","year":"2024","journal-title":"Mol Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumour-infiltrating T cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J Surg Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Escors","year":"2018","journal-title":"Signal Transduction Targeted Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705378","article-title":"CTLA-4 synergizes with PD1\/PD-L1 in the inhibitory tumour microenvironment of intrahepatic cholangiocarcinoma","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: Mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol BioMed"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101686","article-title":"Soluble Tim-3 serves as a tumour prognostic marker and therapeutic target for CD8(+) T cell exhaustion and anti-PD-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1084\/jem.201006432011512c","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumour immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci Transl Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-024-03878-0","article-title":"The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer","volume":"74","author":"Tang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.003","article-title":"LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation","volume":"30","author":"Sung","year":"2022","journal-title":"Mol Ther"},{"key":"B156","first-page":"2023.08.14.553195","volume-title":"bioRxiv","author":"Heij","year":"2023"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31466","article-title":"Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","article-title":"TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies","volume":"16","author":"Cui","year":"2025","journal-title":"Cell Death Dis"},{"key":"B159","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","article-title":"TGF-\u03b2 signalling in the tumour metabolic microenvironment and targeted therapies","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/immuno1030010","article-title":"Multifaceted role of the transforming growth factor \u03b2 on effector T cells and the implication for CAR-T cell therapy","volume":"1","author":"de Folmont","year":"2021","journal-title":"Immuno"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-\u03b2 signalling in Treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signalling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"B166","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12967-023-04829-6","article-title":"DNTGF-\u03b2R armored CAR-T cell therapy against tumours from bench to bedside","volume":"22","author":"Wang","year":"2024","journal-title":"J Transl Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated immunosuppression: MARCH-I induction regulates antigen presentation by macrophages but not dendritic cells","volume":"290","author":"Mittal","year":"2015","journal-title":"J Biol Chem"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1701913","article-title":"Suppression of TGF-\u03b2 and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells","volume":"16","author":"Thepmalee","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i7.107341","article-title":"Role of interleukins in the pathogenesis of cholangiocarcinoma: a literature review","volume":"17","author":"Rafaqat","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12935-020-01687-w","article-title":"Intrahepatic cholangiocarcinoma induced M2-polarized tumour-associated macrophages facilitate tumour growth and invasiveness","volume":"20","author":"Yuan","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.10.037","article-title":"Sustained IL-6\/STAT-3 signalling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing","volume":"132","author":"Isomoto","year":"2007","journal-title":"Gastroenterology"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051083","article-title":"The IL-6\/JAK\/STAT3 axis in cholangiocarcinoma and primary sclerosing cholangitis: unlocking therapeutic strategies through patient-derived organoids","volume":"13","author":"Boden","year":"2025","journal-title":"Biomedicines"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.897368","article-title":"Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma","volume":"13","author":"Kittirat","year":"2022","journal-title":"Front Pharmacol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-025-00687-y","article-title":"Necroptosis-driven T cell activation promotes IL-6-mediated PD-L1 upregulation in cholangiocarcinoma cells: IL-6 gene signature as a biomarker for chemo-immunotherapy response","volume":"20","author":"Lomphithak","year":"2025","journal-title":"Biol Direct"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02386-2","article-title":"New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumour cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming","volume":"41","author":"Colyn","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.3mr0621-616rr","article-title":"Role of IL-6 in dendritic cell functions","volume":"111","author":"Xu","year":"2022","journal-title":"J Leukocyte Biol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.3844","article-title":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation","volume":"173","author":"Park","year":"2004","journal-title":"J Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092134","article-title":"Cancer-associated fibroblast-derived IL-6 determines unfavourable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse","volume":"13","author":"Thongchot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1374967","article-title":"Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma","volume":"15","author":"Gu","year":"2024","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203542","article-title":"Tumour immune microenvironment in intrahepatic cholangiocarcinoma: regulatory mechanisms, functions, and therapeutic implications","volume":"16","author":"Ricci","year":"2024","journal-title":"Cancers"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.clicom.2023.11.002","article-title":"Immune microenvironment and progress in immunotherapy of cholangiocarcinoma","volume":"4","author":"Shao","year":"2023","journal-title":"Clin Immunol Commun"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11061062","article-title":"Cholangiocarcinoma in the era of immunotherapy","volume":"11","author":"Manthopoulou","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11893-4","article-title":"Engineered triple inhibitory receptor resistance improves anti-tumour CAR-T cell performance via CD56","volume":"10","author":"Zou","year":"2019","journal-title":"Nat Commun"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06453-y","article-title":"Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 and secreting anti-PD-L1 scFv","volume":"23","author":"Phanthaphol","year":"2025","journal-title":"J Transl Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01995-y","article-title":"MDSC: a new potential breakthrough in CAR-T therapy for solid tumours","volume":"22","author":"Abdalsalam","year":"2024","journal-title":"Cell Commun Signalling"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003237","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumour-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumours","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.323","article-title":"The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers","volume":"4","author":"Ren","year":"2023","journal-title":"MedComm"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol Rev"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.740827","article-title":"Myeloid-derived suppressor cells: a multifaceted accomplice in tumour progression","volume":"9","author":"Cheng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0691","article-title":"Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor\u2013mediated natural killer cell function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B196","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumour immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp Haematol Oncol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumour-associated macrophages remodel the suppressive tumour immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1261749","article-title":"Tumour-associated macrophages: versatile players in the tumour microenvironment","volume":"11","author":"Ji","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumour-associated macrophages: an effective player of the tumour microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12967-024-06036-3","article-title":"Modulating tumour-associated macrophages through CSF1R inhibition: a potential therapeutic strategy for HNSCC","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166487","article-title":"Reprogramming tumour-associated macrophages as a unique approach to target tumour immunotherapy","volume":"14","author":"Khan","year":"2023","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumours","volume":"51","author":"Chen","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-025-03697-y","article-title":"Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies","volume":"25","author":"Nasiri","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0879","article-title":"Biomarkers for the diagnosis of cholangiocarcinoma: a systematic review","volume":"98","author":"Tshering","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B205","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"B206","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","article-title":"Identification of tumour antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.010","article-title":"Immunobiology of cholangiocarcinoma","volume":"79","author":"Tomlinson","year":"2023","journal-title":"J Hepatol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma \u2014 novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061493","article-title":"Biomarkers and genetic markers of hepatocellular carcinoma and cholangiocarcinoma\u2014what do we already know","volume":"14","author":"Baj","year":"2022","journal-title":"Cancers"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000688","article-title":"Immunogenomics of cholangiocarcinoma","volume":"82","author":"Gehl","year":"2025","journal-title":"Hepatology"},{"key":"B211","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gutjnl-2023-331480","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25627","article-title":"Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue","volume":"56","author":"Harada","year":"2012","journal-title":"Hepatology"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumours: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1159\/000543806","article-title":"Multi-targeting CAR-T cell strategies to overcome immune evasion in lymphoid and myeloid Malignancies","volume":"48","author":"Peter","year":"2025","journal-title":"Oncol Res Treat"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603757","article-title":"CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy","volume":"16","author":"dos Reis","year":"2025","journal-title":"Front Immunol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156375","article-title":"Modulating metabolism to improve the therapeutic outcomes of CAR cell therapies: From bench to bedside","volume":"173","author":"Li","year":"2025","journal-title":"Metabolism"},{"key":"B219","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00432-024-05723-4","article-title":"Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma","volume":"150","author":"Sang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115206","article-title":"Tumour-induced metabolic immunosuppression: mechanisms and therapeutic targets","volume":"44","author":"Ricci","year":"2025","journal-title":"Cell Rep"},{"key":"B221","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0871","article-title":"Regulatory role of CD39 and CD73 in tumour immunity","volume":"20","author":"Kaplinsky","year":"2024","journal-title":"Future Oncol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.7150\/jca.51038","article-title":"High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma","volume":"12","author":"Xu","year":"2021","journal-title":"J Cancer"},{"key":"B224","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12957-023-02970-6","article-title":"Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma","volume":"21","author":"Sun","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumour microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626369","article-title":"From\u00a0spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumours","volume":"16","author":"Jassin","year":"2025","journal-title":"Front Immunol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front Immunol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.004","article-title":"From bench to bedside: single-cell analysis for cancer immunotherapy","volume":"39","author":"Davis-Marcisak","year":"2021","journal-title":"Cancer Cell"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.019","article-title":"Mapping the cancer surface proteome in search of target antigens for immunotherapy","volume":"32","author":"Di Meo","year":"2024","journal-title":"Mol Ther"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70396","article-title":"Cancer therapy resistance from a spatial-omics perspective","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin Transl Med"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s44320-025-00101-9","article-title":"Spatial proteomics in translational and clinical research","volume":"21","author":"Horvath","year":"2025","journal-title":"Mol Syst Biol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412740","article-title":"Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area","volume":"12","author":"Zuyin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1017\/cbo9780511722226.019","article-title":"Spatial single-cell proteomics landscape decodes the tumour microenvironmental ecosystem of intrahepatic cholangiocarcinoma","author":"Hong","year":"2025","journal-title":"Hepatology"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100739","article-title":"Armouring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","volume":"24","author":"Carcopino","year":"2024","journal-title":"Immuno-Oncology Technol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1643941","article-title":"Current strategies for armouring chimeric antigen receptor T-cells to overcome barriers of the solid tumour microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.22464411","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008275","article-title":"CARs are sharpening their weapons","volume":"12","author":"Pievani","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14871","article-title":"T-cell-based immunotherapies for haematological cancers, part B: a SWOT analysis of adoptive cell therapies","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"},{"key":"B241","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumour stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"B242","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumours","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol Ther"},{"key":"B243","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/btt.s291768","article-title":"Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.108036","article-title":"From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumour recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.832765","article-title":"Special chimeric antigen receptor (CAR) modifications of T cells: a review","volume":"12","author":"Miao","year":"2022","journal-title":"Front Oncol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumours: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B248","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumours: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J Haematol Oncol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumours: challenges and breakthroughs","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B250","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol Cancer"},{"key":"B251","volume-title":"Clinical study of chimeric HER-2 antigen receptor-modified T cells in chemotherapy refractory HER-2 advanced solid tumours","year":"2013"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3059","article-title":"Thymoquinone induces G2\/M arrest, inactivates PI3K\/Akt and nuclear factor-\u03baB pathways in human cholangiocarcinomas both in vitro and in vivo","volume":"31","author":"Xu","year":"2014","journal-title":"Oncol Rep"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgr032","article-title":"Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signalling pathways","volume":"32","author":"Prakobwong","year":"2011","journal-title":"Carcinogenesis"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s112364","article-title":"Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells","volume":"10","author":"Kwak","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B255","doi-asserted-by":"publisher","first-page":"16059","DOI":"10.1038\/s41598-024-66945-7","article-title":"Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2\/glutamine pathway","volume":"14","author":"Thongpon","year":"2024","journal-title":"Sci Rep"},{"key":"B256","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumour genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"B264","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/lci2.43","article-title":"Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma","volume":"3","author":"Adeva","year":"2022","journal-title":"Liver Cancer Int"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae163","article-title":"PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma","volume":"29","author":"Mohan","year":"2024","journal-title":"Oncologist"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1016\/j.sipas.2021.100028","article-title":"Immunotherapy in cholangiocarcinoma: From concept to clinical trials","volume":"5","author":"Yao","year":"2021","journal-title":"Surg Pract Sci"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200872","article-title":"CAR-T cell therapy: Advances in digestive system Malignant tumours","volume":"32","author":"Xu","year":"2024","journal-title":"Mol Ther: Oncol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010739","article-title":"SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development","volume":"13","author":"Emens","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front Immunol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116","article-title":"CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumours","volume":"15","author":"Khan","year":"2025","journal-title":"Front Immunol"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.15212\/hod-2022-0003","article-title":"Novel bayesian adaptive early phase designs to accelerate the development of CAR T-cell therapy","volume":"1","author":"Yuan","year":"2022","journal-title":"Haematol Oncol Discov"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3865.2014.06.04","article-title":"Adaptive clinical trial designs in oncology","volume":"3","author":"Zang","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"B275","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/17407745231220661","article-title":"Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies","volume":"21","author":"Zang","year":"2024","journal-title":"Clin Trials"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumour toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.01.035","article-title":"Engineering resilient CAR T cells for immunosuppressive environment","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol Ther"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation\u00a0cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B282","doi-asserted-by":"publisher","first-page":"19","DOI":"10.20517\/2394-5079.2025.15","article-title":"Glucose metabolic dysregulation and oxidative stress in cholangiocarcinoma: molecular mechanisms, oncogenic drivers, and novel therapeutic targets","volume":"11","author":"Makamas","year":"2025","journal-title":"Hepatoma Res"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4342820\/v1","article-title":"The glucose transporter 5 enhances CAR-T cell metabolic function and anti-tumour durability","author":"Valenti\u0107","year":"2024","journal-title":"Res Sq"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.006","article-title":"Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukaemia with therapeutic potential","volume":"30","author":"Chen","year":"2016","journal-title":"Cancer Cell"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaf018","article-title":"GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions","volume":"5","author":"Page","year":"2025","journal-title":"Immunother Adv"},{"key":"B286","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2025.02.004","article-title":"Metabolic engineering to facilitate anti-tumour immunity","volume":"43","author":"Schild","year":"2025","journal-title":"Cancer Cell"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1646897","article-title":"Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000188","article-title":"CAR-T cells: Future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumours","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual-target chimeric antigen receptor T-cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J Immunol Res"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0101","article-title":"Programming CAR T cell tumour recognition: Tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"B293","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumours","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs","volume":"14","author":"Lv","year":"2024","journal-title":"Front Oncol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13121573","article-title":"Synergistic anti-cancer effects of curcumin and thymoquinone against melanoma","volume":"13","author":"Mohd","year":"2024","journal-title":"Antioxid (Basel)"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00295","article-title":"Thymoquinone as a potential adjuvant therapy for cancer treatment: Evidence from preclinical studies","volume":"8","author":"Mostofa","year":"2017","journal-title":"Front Pharmacol"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020166","article-title":"Recent updates on local ablative therapy combined with chemotherapy for extrahepatic cholangiocarcinoma: Photodynamic therapy and radiofrequency ablation","volume":"30","author":"Inoue","year":"2023","journal-title":"Curr Oncol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12893-025-02778-z","article-title":"Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: A comprehensive review","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Surg"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006226","article-title":"Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy","volume":"11","author":"Tang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B302","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Haematol Oncol"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070935","article-title":"Overcoming immune barriers in allogeneic CAR-NK therapy: From multiplex gene editing to AI-driven precision design","volume":"15","author":"Kim","year":"2025","journal-title":"Biomolecules"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR macrophages: A promising novel immunotherapy for solid tumours and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"biomark Res"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002741","article-title":"CARs and beyond: Tailoring macrophage-based cell therapeutics to combat solid Malignancies","volume":"9","author":"Abdin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188547","article-title":"Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages","volume":"1876","author":"Santoni","year":"2021","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13060654","article-title":"CAR beyond \u03b1\u03b2 T cells: Unleashing NK cells, macrophages, and \u03b3\u03b4 T lymphocytes against solid tumours","volume":"13","author":"Xian","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B308","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u03b3\u03b4 T cells: Pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumours","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumours: A phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1080","article-title":"\u03b3\u03b4 T cells in cancer: A small population of lymphocytes with big implications","volume":"8","author":"Raverdeau","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B316","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41467-022-29012-1","article-title":"Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma","volume":"13","author":"Zakeri","year":"2022","journal-title":"Nat Commun"},{"key":"B317","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","article-title":"Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumour: A case study for cholangiocarcinoma","volume":"7","author":"Alnaggar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B318","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jvir.2021.09.012","article-title":"Clinical safety and efficacy of locoregional therapy combined with adoptive transfer of allogeneic \u03b3\u03b4 T cells for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"33","author":"Zhang","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"B319","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41598-024-51794-1","article-title":"Human V\u03b39V\u03b42 T cell expansion and their cytotoxic responses against cholangiocarcinoma","volume":"14","author":"Sawaisorn","year":"2024","journal-title":"Sci Rep"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1007\/s44345-025-00014-y","article-title":"Emerging therapeutic approaches for cholangiocarcinoma: harnessing natural compounds and targeted therapies with proposed cellular mechanism","volume":"2","author":"Ahmad","year":"2025","journal-title":"Discover Mol"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.01984.x","article-title":"Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells","volume":"29","author":"Lang","year":"2009","journal-title":"Liver Int"},{"key":"B322","unstructured":"FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma FDA\n          \n          2022"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233929","article-title":"FGFR inhibitors in cholangiocarcinoma-a novel yet primary approach: Where do we stand now and where to head next in targeting this axis","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"key":"B324","volume-title":"Phase 1\/2 study of TAS-120 in patients with advanced solid tumours harbouring FGF\/FGFR aberrations","year":"2014"},{"key":"B325","volume-title":"A phase 3, multicentre, randomized, double-blind, placebo-controlled study of AG-120 in previously-treated subjects with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation","year":"2016"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumour infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118300","article-title":"CAR-T in solid tumours: Blazing a new trail through the brambles","volume":"260","author":"Guo","year":"2020","journal-title":"Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:48Z","timestamp":1778219688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":327,"alternative-id":["10.3389\/fimmu.2026.1757504"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1757504","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1757504"}}